Envoy Medical (COCHW) EBITDA (2021 - 2026)

Envoy Medical has disclosed EBITDA across 6 years of filings, most recently posting -$4.4 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$4.4 million, up 12.82% year-over-year; the trailing twelve-month figure through Mar 2026 was -$23.1 million (down 18.4% YoY), and the FY2025 annual result was -$23.8 million, down 14.2% from the prior year.
• EBITDA came in at -$4.4 million for Q1 2026 at Envoy Medical, up from -$6.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.6 million in Q3 2023 to a low of -$13.3 million in Q1 2023.
• The 5-year median for EBITDA is -$5.0 million (2025), against an average of -$5.5 million.
• Peak annual rise in EBITDA reached 216.39% in 2023, while the deepest fall reached 1369.67% in 2023.
• Envoy Medical's EBITDA stood at -$11.5 million in 2022, then surged by 57.35% to -$4.9 million in 2023, then climbed by 5.66% to -$4.6 million in 2024, then plunged by 42.55% to -$6.6 million in 2025, then jumped by 33.92% to -$4.4 million in 2026.
• The last three EBITDA figures came in at -$4.4 million (Q1 2026), -$6.6 million (Q4 2025), and -$6.5 million (Q3 2025), per Business Quant data.